Transcriptome analysis of Hela cells treated with the PARP inhibitor Olaparib.
In total, 17,118 and 16,786 transcripts were detected in olaparib- and DMSO-treated cells, respectively. Analysis of differentially expressed genes (DEGs) revealed 866 genes, including 503 upregulated and 363 downregulated genes in olaparib-treated cells). Volcano plots indicated the upregulation of inflammatory cytokine-related genes . Enrichment analyses using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database20,21 identified inflammation-related pathways as prominently upregulated in olaparib-treated cells, with five of the top 10 pathways involving inflammation-related genes. Dot plot analyses also confirmed the upregulation of inflammatory hallmarks, such as TNFA signaling via NF?B, inflammatory response, IL2-STAT5 signaling and interferon gamma response, in olaparib-treated cells. Furthermore, the GSEA determined significant enrichment of inflammatory cytokine-related KEGG pathways, including cytokine–cytokine receptor interaction, JAK-STAT signaling, and Rig I like receptor signaling pathways, as well as inflammatory hallmarks such as TNFA signaling via NF?B, interferon alfa response, and interferon gamma response in olaparib-treated cells. Overall design: HeLa cells were treated with 10 µM olaparib or DMSO for 72 h, where moderate anti-proliferation with considerable DNA damage was observed, and were subjected to RNA sequencing (RNA-seq)